Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia - Tabular View

Tracking Information
First Received Date ^ICMJE	May 2, 2002
Last Updated Date	July 18, 2006
Start Date ^ICMJE	September 2001
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00034801 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
Official Title ^ICMJE	A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression
Brief Summary	This is a research study comparing the safety and efficacy of two active study medications
Detailed Description
Study Phase	Phase IV
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Condition ^ICMJE	Depression Schizophrenia Schizoaffective Disorder
Intervention ^ICMJE	Drug: olanzapine Drug: ziprasidone
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	378
Completion Date	March 2003
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Male or female subjects 18-60 years of age Female subjects of childbearing potential must be using a medically accepted means of contraception Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol Subjects must be considered reliable Exclusion Criteria: Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry Female subjects who are either pregnant or nursing Uncorrected hypothyroidism or hyperthyroidism Narrow-angle glaucoma
Gender	Both
Ages	18 Years to 60 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00034801
Responsible Party
Study ID Numbers ^ICMJE	5529, F1D-US-HGJU
Study Sponsor ^ICMJE	Eli Lilly and Company
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Eli Lilly and Company
Verification Date	July 2006
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP